Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor α-chain are excluded from the analysis

Journal of Clinical Investigation

Volumn 118, Issue 10, 2008, Pages 3411-3419

  Michel, Laure ^a,b,c   Berthelot, Laureline ^a,c   Pettré, Ségolène ^a,c   Wiertlewski, Sandrine ^b   Lefrère, Fabienne ^b   Braudeau, Cécile ^a,c   Brouard, Sophie ^a,c   Soulillou, Jean Paul ^a,c   Laplaud, David Axel ^a,b  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CELL FUNCTION; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CYTOKINES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, INTERLEUKIN-7; T-LYMPHOCYTES, REGULATORY;

EID: 55849126729     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI35365     Document Type: Article

References (39)

1. Baecher-Allan, C., and Hafler, D.A. 2006. Human regulatory T cells and their role in autoimmune disease. Immunol. Rev. 212:203-216.
2. Tang, Q., and Bluestone, J.A. 2006. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev. 212:217-237.
3. Asano, M., Toda, M., Sakaguchi, N., and Sakaguchi, S. 1996. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184:387-396.
4. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155:1151-1164.
5. Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
6. Khattri, R., Cox, T., Yasayko, S.A., and Ramsdell, F. 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4:337-342.
7. Hori, S., Nomura, T., and Sakaguchi, S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057-1061.
8. Allan, S.E., et al. 2005. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J. Clin. Invest. 115:3276-3284.
9. Morgan, M.E., et al. 2005. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum. Immunol. 66:13-20.
10. Ziegler, S.F. 2007. FOXP3: not just for regulatory T cells anymore. Eur. J. Immunol. 37:21-23.
11. Dieckmann, D., Plottner, H., Berchtold, S., Berger, T., and Schuler, G. 2001. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med. 193:1303- 1310.
12. Thornton, A.M., and Shevach, E.M. 2000. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164:183-190.
13. Seddiki, N., et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203:1693-1700.
14. Liu, W., et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203:1701-1711.
15. Hohlfeld, R., and Wekerle, H. 2004. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. U. S. A. 101(Suppl. 2):14599-14606.
16. Sospedra, M., and Martin, R. 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23:683-747.
17. Hellings, N., et al. 2001. T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controls. J. Neurosci. Res. 63:290-302.
18. Putheti, P., Pettersson, A., Soderstrom, M., Link, H., and Huang, Y.M. 2004. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J. Clin. Immunol. 24:155-161.
19. Haas, J., et al. 2005. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35:3343-3352.
20. Kumar, M., et al. 2006. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J. Neuroimmunol. 180:178-184.
21. Viglietta, V., Baecher-Allan, C., Weiner, H.L., and Hafler, D.A. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:971-979.
22. Venken, K., et al. 2008. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology. 123:79-89.
23. Huan, J., et al. 2005. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81:45-52.
24. Sakaguchi, S., et al. 2006. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol. Rev. 212:8-27.
25. Mazzucchelli, R., and Durum, S.K. 2007. Interleukin-7 receptor expression: intelligent design. Nat. Rev. Immunol. 7:144-154.
26. Roncarolo, M.G., and Battaglia, M. 2007. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans. Nat. Rev. Immunol. 7:585-598.
27. McFarland, H.F., and Martin, R. 2007. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 8:913-919.
28. Hafler, D.A., et al. 2007. Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. 357:851-862.
29. Lundmark, F., et al. 2007. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat. Genet. 39:1108-1113.
30. Gregory, S.G., et al. 2007. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat. Genet. 39:1083-1091.
31. Baecher-Allan, C., Brown, J.A., Freeman, G.J., and Hafler, D.A. 2001. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167:1245-1253.
32. Baecher-Allan, C.M., and Hafler, D.A. 2005. Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+CD25+ T cells. Clin. Immunol. 117:192; discussion 193.
33. Beissert, S., Schwarz, A., and Schwarz, T. 2006. Regulatory T cells. J. Invest. Dermatol. 126:15-24.
34. Josien, R., et al. 1999. Recombinant IFN-gamma abrogates allograft tolerance induced by donor-specific blood transfusion by restoring alloantibody production. Eur. J. Immunol. 29:317-326.
35. Codarri, L., et al. 2007. Expansion and tissue infiltration of an allospecific CD4+CD25+CD45RO+IL-7R{alpha}high cell population in solid organ transplant recipients. J. Exp. Med. 204:1533-1541.
36. Venken, K., et al. 2008. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: recovery of memory Treg homeostasis during disease progression. J. Immunol. 180:6411-6420.
37. McDonald, W.I., et al. 2001. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50:121-127.
38. Kurtzke, J.F. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1444-1452.
39. Braudeau, C., et al. 2007. Variation in numbers of CD4(+)CD25(high) FOXP3(+) T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl. Int. 20:845-855.